In a model of adults with type 2 diabetes failing metformin, the cost per patient reaching HbA1c below 7% was lowest with liraglutide 1.2 mg ($7,993) and highest with sitagliptin ($11,570).
In plain wordsIn a cost model of adults with type 2 diabetes, reaching the HbA1c target cost least with liraglutide 1.2 mg and most with sitagliptin.
- Peptide
- Liraglutide
- Outcome
- Not applicableCost per patient achieving HbA1c below 7%
- Study
n: not reported in source
- Comparator
- Sitagliptin 100 mg
- Outcome group
- Cost-effectiveness · Metabolic and weight
Measurements
- Cost per patient with HbA1c <7%
- 7993 USD
- liraglutide 1.2 mg
- Cost per patient with HbA1c <7%
- 11,570 USD
- sitagliptin
Source sentences
The cost per patient achieving an HbA1c less than 7% was lowest for patients receiving liraglutide 1.2 mg ($7,993) and highest for patients receiving sitagliptin ($11,570).
1 context sentence(design, population, supporting numbers)
Data were taken from a 52-week randomized, controlled trial (NCT00700817) in which adults with type 2 diabetes (mean age = 55 years, HbA1c = 8.4%, body mass index = 33 kg/m2) failing metformin monotherapy were randomly allocated to receive either liraglutide 1.2 mg, liraglutide 1.8 mg, or sitaglipti…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.